The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout
| Autor: | Yuan-Yuan Huang, Zhuang Ye, San-Wei Gu, Zhen-Yu Jiang, Ling Zhao |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Journal of International Medical Research, Vol 48 (2020) |
| Druh dokumentu: | article |
| ISSN: | 1473-2300 03000605 |
| DOI: | 10.1177/0300060520902950 |
| Popis: | Objective To measure the effect of febuxostat on the serum levels of uric acid (sUA) and the proinflammatory cytokines interleukin (IL)-6, IL-17 and tumour necrosis factor-α (TNF-α) in Chinese Han patients with gout and hyperuricaemia. Methods This randomized, double-blind, placebo-controlled pilot study enrolled patients with gout and hyperuricaemia (sUA ≥ 8 mg/dl). Patients were randomized to receive either febuxostat 80 mg or placebo once daily for 24 weeks. The serum levels of sUA, IL-6, IL-17 and TNF-α were measured at weeks 0 (baseline), 2, 4, 8, 12, 16 and 24. Baseline clinical and demographic characteristics were recorded for all patients. Results A total of 156 patients were randomized: placebo group ( n = 78) and febuxostat group ( n = 78). The febuxostat group showed a significantly greater reduction in sUA compared with the placebo group. Serum uric acid concentration was reduced below 8 mg/dl in 46 of 61 patients (75.4%) by week 24. There were also reductions in the serum levels IL-6, IL-17 and TNF-α in the febuxostat group. In the febuxostat group, 10 of 78 patients (12.82%) discontinued treatment due to adverse drug reactions. Conclusion Febuxostat reduced the levels of sUA, TNF-α, IL-6 and IL-17, but there were some side-effects. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|